Eli Lilly & Co. will acquire Loxo Oncology Inc. for about $8 billion in cash, the second multibillion-dollar cancer deal of the year by a major U.S. pharmaceutical company.
The purchase is Indianapolis-based Lilly’s biggest takeover ever, according to data compiled by Bloomberg. Loxo holders will get $235 per share in cash, the companies said in a statement Jan. 7, The Stamford, Conn.-based biotechnology company is developing cancer treatments that target a tumor’s genetic markers regardless of where in the body they’re located.
Lilly is offering a rich premium -- 68 percent above Loxo’s closing stock price Jan. 4 and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.